Chandra Armstrong, MD
Family Medicine · Decatur, GANPI 1376625053
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,620 of the $8,222 with a category attached, or 80.5%. It is spread thinly across 22 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,359 and has fallen 65.1% since, to $824 in 2025. Among family medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Genentech USA, Inc.$1K
- Lilly USA, LLC$974
- Bayer$851
- AstraZeneca$809
- plus $2K from 16 others
Across 63 payments — averaging $4447.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$237K
- Chiesi USA, Inc.$43K
What the payments were for
- Consulting fees$3504%
- Travel & lodging$1,07713%
- Food & beverage$6,62081%
- Education$1752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 73 | $1,335 |
| AbbVie(2 entities) | 49 | $1,240 |
| Genentech USA, Inc. | 7 | $1,126 |
| Lilly USA, LLC | 53 | $974 |
| Bayer | 29 | $851 |
| AstraZeneca | 40 | $809 |
| Boehringer Ingelheim | 19 | $499 |
| Astellas Pharma US Inc | 12 | $476 |
| Johnson & Johnson | 10 | $184 |
| Abbott | 7 | $134 |
| Sanofi-aventis U.S. LLC | 8 | $124 |
| Merck | 7 | $118 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Pfizer | 2 | $48 |
| Amgen | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $47 |
| GSK | 2 | $47 |
| Coloplast | 1 | $30 |
| Exact Sciences | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Echosens North America, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,222 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 122 | $161,575 |
| OzempicSemaglutide | 73 | $90,239 |
| MounjaroTirzepatide | 59 | $81,858 |
| FarxigaDapagliflozin Propanediol | 47 | $61,398 |
| TrulicityDulaglutide | 45 | $59,965 |
| EliquisApixaban | 23 | $31,057 |
| KerendiaFinerenone | 17 | $27,858 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $22,892 |
| JanuviaSitagliptin Phosphate | 12 | $19,847 |
| RybelsusSemaglutide | 12 | $11,245 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,377 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,987 |
| Novolog FlexpenInsulin Aspart | 16 | $6,542 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $4,030 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $3,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $499 | $184,466141 claims |
| Lilly USA, LLCMounjaro, Trulicity | $974 | $141,824104 claims |
| Novo NordiskOzempic, Rybelsus | $1,335 | $101,48485 claims |
| AstraZenecaFarxiga | $809 | $61,39847 claims |
| PfizerEliquis | $48 | $31,05723 claims |
| BayerKerendia | $851 | $27,85817 claims |
| MerckJanuvia | $118 | $19,84712 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $47 | $18,36428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Decatur
- Regina WangDecatur$25K
- Mohammed AliDecatur$23K
- Jeffrey KingsleyColumbus$404K
- Debbie HaginsSavannah$279K
- Yolanda WadeTyrone$233K
- Julian HutchinsWarrenton$222K
- Nadine Halliburton-FosterCumming$219K
- Contessa MetcalfeAtlanta$157K
- Elmore AlexanderStone Mountain$155K
- Bantwal BaligaColumbus$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.